Keros Therapeutics, Inc. (KROS)
$11.95+2.66%Close
BUYRECOVERY · day 36
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $382M
- Beta
- 1.02
- P/E (TTM)
- -2.98
- Short % float
- 3.89%
- Days to cover
- 5.6
- SI change
- -14.4%
- 1W
- +5.19%
- 1M
- +6.98%
- vs SPY 1W
- +4.03%
- vs SPY 1M
- +3.99%
Industry peers
FMP comparable companies · ranked by market cap
- ABSIBUYAbsci Corporation$1.7BCRISISQ 3$10.27+13.65%
- VTYXVentyx Biosciences, Inc.$1.0B$14.00
- MLTXSELLMoonLake Immunotherapeutics$921MCRISISQ -0$10.95+2.27%
- CRVSSELLCorvus Pharmaceuticals, Inc.$888MCRISISQ 13$10.56+3.04%
- RIGLBUYRigel Pharmaceuticals, Inc.$853MBULLQ 9$46.11+0.74%
- OLMASELLOlema Pharmaceuticals, Inc.$692MCRISISQ -1$7.92+0.00%
- VSTMBUYVerastem, Inc.$681MRECOVERYQ 4$7.75+3.33%
- CTMXSELLCytomX Therapeutics, Inc.$557MCRISISQ 7$2.56+4.05%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
Company news
FAQ
- What is LOPJLB’s current signal on KROS?
- LOPJLB’s latest quantitative signal on Keros Therapeutics, Inc. (KROS) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is KROS in?
- Keros Therapeutics, Inc. (KROS) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does Keros Therapeutics, Inc. (KROS) do?
- Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specif…